StockData
20/20 Biolabs, Inc. logo

20/20 Biolabs, Inc. (AIDX) stock

AIDXNasdaqServices-Testing LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/3070% below fair value
$0.19−0.00 (-1.01%)

Close on Nov 18, 2026Market cap $2.37MP/E –Yield –

20/20 Biolabs gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

For fiscal 2025 it was $604.54K, up 67.8% from the year before.

Annual gross profit

PeriodPeriod endValueChange
FY2025Dec 31, 2025$604.54K+67.8%
FY2024Dec 31, 2024$360.31K–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$304.73K–
Q1 FY2026Mar 31, 2026$62.88K–
Q2 FY2025Jun 30, 2025$163.26K–
Q1 FY2025Mar 31, 2025$165.80K–

More 20/20 Biolabs figures

See a number that looks wrong?